These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial. Williams T; Tur C; Eshaghi A; Doshi A; Chan D; Binks S; Wellington H; Heslegrave A; Zetterberg H; Chataway J Mult Scler; 2022 Oct; 28(12):1913-1926. PubMed ID: 35946107 [TBL] [Abstract][Full Text] [Related]
30. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies. Hernandez L; O'Donnell M; Postma M; Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685 [TBL] [Abstract][Full Text] [Related]
31. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376 [TBL] [Abstract][Full Text] [Related]
32. Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis. Broos JY; Loonstra FC; de Ruiter LRJ; Gouda M; Fung WH; Schoonheim MM; Heijink M; Strijbis EMM; Teunissen C; Killestein J; de Vries HE; Giera M; Uitdehaag BMJ; Kooij G Neurology; 2023 Aug; 101(5):e533-e545. PubMed ID: 37290971 [TBL] [Abstract][Full Text] [Related]
33. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436 [TBL] [Abstract][Full Text] [Related]
34. Disease characteristics of idiopathic transverse myelitis with serum neuronal and astroglial damage biomarkers. Kim KW; Lee EJ; Kim SY; Jung HJ; Kim HJ; Kim S; Kim H; Seo D; So J; Kim J; Kim H; Kim KK; Lim YM Sci Rep; 2023 Mar; 13(1):3988. PubMed ID: 36894677 [TBL] [Abstract][Full Text] [Related]
35. Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. Koch MW; Mostert J; Repovic P; Bowen JD; Uitdehaag B; Cutter G Neurology; 2021 Jan; 96(1):e111-e120. PubMed ID: 33106389 [TBL] [Abstract][Full Text] [Related]
36. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Petzold A; Eikelenboom MJ; Gveric D; Keir G; Chapman M; Lazeron RH; Cuzner ML; Polman CH; Uitdehaag BM; Thompson EJ; Giovannoni G Brain; 2002 Jul; 125(Pt 7):1462-73. PubMed ID: 12076997 [TBL] [Abstract][Full Text] [Related]
37. Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder: Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein. Hyun JW; Kim Y; Kim SY; Lee MY; Kim SH; Kim HJ Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33846219 [TBL] [Abstract][Full Text] [Related]
38. An enrichment strategy for clinical trials in SPMS. Koch MW; Metz L; Cutter G Mult Scler; 2021 Oct; 27(12):1884-1893. PubMed ID: 33404355 [TBL] [Abstract][Full Text] [Related]
39. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials. Leppert D; Kropshofer H; Häring DA; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J Neurology; 2022 May; 98(21):e2120-e2131. PubMed ID: 35379762 [TBL] [Abstract][Full Text] [Related]